drugset / Trial / NCT00190580
Kanagawa Valsartan Trial (KVT): Effects of Valsartan on Renal and Cardiovascular Disease
Phase 4
Completed
312 enrolled
KVT-Study Group
Kitasato University · collabShowa University · collabSt. Marianna University School of Medicine · collabTokai University · collabYokohama City University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to prove the hypothesis that the progression of renal and cardiovascular disease is more efficiently prevented when the angiotensin II receptor blocker valsartan is added to conventional antihypertensive therapy.
Timeline
- Start
- 2003-02
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valsartan | Unknown | 20 mg | — |
| Subject | Valsartan | Unknown | 180 mg | — |